New data shows firazyr safe for kids with swelling attacks
NCT ID NCT05509569
First seen Nov 17, 2025 · Last updated May 21, 2026 · Updated 24 times
Summary
This study looked at the safety and effectiveness of the drug Firazyr (icatibant) in 32 children and teenagers (ages 2 to 17) with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Doctors gave the injection during an attack and watched for side effects and how quickly symptoms went away over 3 months. The goal was to see if the drug is safe and works well for younger patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Takeda selected site
Tokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.